Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/07/2025 07:14 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [08/06/2025 07:28 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [07/31/2025 07:25 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [07/23/2025 07:06 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [07/18/2025 13:39 PDT] Benitec Biopharma Inc. (NASDAQ:BNTC), Down By 100% ($12.44) From $12.44 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions